A multigene panel can reveal that a woman carries a pathogenic variant associated with elevated breast cancer risk, but new research suggests that receiving this information does not automatically translate into consistent participation in recommended screening. The study, published in Breast Cancer Research and Treatment, examines screening adherence among women whose genetic testing identified pathogenic variants in moderate-risk breast cancer genes, as well as women whose risk was considered unusually high for non-genetic reasons. Its central question is increasingly important as genetic testing becomes faster, cheaper and more widely available: when a test identifies a meaningful risk, do patients change their long-term screening behavior?
Unlike testing focused only on the two best-known hereditary breast cancer genes, BRCA1 and BRCA2, multigene panels analyze numerous genes at the same time. These panels can identify variants in genes such as ATM, CHEK2 and PALB2, among others, that may increase breast cancer risk but do not always carry the extremely high lifetime risk associated with some BRCA1 or BRCA2 alterations. The clinical challenge is that risk is not uniform across these genes. It can depend on the specific variant, family history, age, reproductive history and other factors. A pathogenic variant is not a diagnosis of cancer; it is a molecular warning that can influence the intensity and timing of surveillance.
The researchers focused on women who fell into two clinically important categories. The first group carried pathogenic variants in genes generally classified as conferring moderate breast cancer risk. The second group did not necessarily have a high-risk genetic finding but had an empirically increased risk, meaning that their estimated risk was elevated on the basis of personal or family history, prior breast abnormalities or formal risk calculations. These risk models combine demographic and clinical variables to estimate the probability of developing breast cancer over a defined period or across a lifetime. In practice, women in either group may be advised to begin screening earlier, undergo annual magnetic resonance imaging in addition to mammography, or receive more specialized counseling.
The study addresses a gap between risk communication and preventive action. After genetic counseling, women may understand that screening is important, yet maintaining a schedule can be difficult. Mammography requires repeated appointments, while breast magnetic resonance imaging is more expensive, takes longer and usually involves intravenous contrast. MRI also detects more suspicious areas than mammography, which can lead to additional imaging or biopsies even when cancer is not present. These practical and psychological burdens can affect adherence. Some women may also misunderstand the meaning of a moderate-risk result, interpreting it either as a guarantee that cancer will develop or as a finding too weak to justify intensive surveillance.
Adherence is particularly complex because recommended screening is not identical for every patient. Mammography uses low-dose X-rays to identify structural changes such as masses, distortions and microcalcifications. MRI, by contrast, tracks the movement of contrast material through breast tissue and can reveal patterns of abnormal blood supply associated with tumors. Dense breast tissue can make mammographic interpretation more difficult, while MRI may detect lesions that mammography misses. For women with inherited susceptibility or a calculated lifetime risk above commonly used clinical thresholds, combining these techniques can improve the chance of detecting cancer at an earlier stage. The benefit, however, depends on completing examinations at the recommended intervals rather than attending sporadically.
By examining women after multigene panel testing, the research captures what happens beyond the moment of disclosure. Genetic testing is often portrayed as a decisive event: a result arrives, risk is explained and a surveillance plan is created. Real-world care is less linear. Results may be delivered through different clinical services, and follow-up can involve primary-care physicians, genetic counselors, breast specialists, radiologists and insurers. A patient may receive a recommendation for annual MRI but encounter scheduling delays, cost barriers or uncertainty about which clinician is responsible for ordering the scan. The study’s focus on actual screening behavior therefore offers a practical test of whether genetic information is being converted into sustained preventive care.
The findings carry implications for precision medicine, which seeks to tailor healthcare to a person’s biological and clinical characteristics. A genetic result is useful only when it produces an action that improves health outcomes. If women with moderate-risk variants or empirically elevated risk do not consistently complete recommended imaging, healthcare systems may need stronger follow-up mechanisms. These could include automated reminders, direct scheduling, navigation by genetic counselors, coordination between testing laboratories and clinics, and clearer explanations of why both mammography and MRI may be recommended. The results also highlight the importance of distinguishing moderate risk from average risk without minimizing the significance of either category.
The study also underscores the need for caution when interpreting screening adherence as a measure of patient motivation. Missed or delayed examinations may reflect structural obstacles rather than a lack of concern. Insurance coverage for MRI differs across jurisdictions and plans, and the requirements for prior authorization can be difficult to navigate. Transportation, work schedules, caregiving responsibilities and fear of false-positive results may all influence attendance. Researchers and clinicians must also account for differences in how adherence is measured, including whether a woman completes imaging within a narrow annual window or within a broader interval. These technical details can substantially change the apparent level of compliance.
As genetic testing expands, the number of people receiving results that fall between clearly low and clearly high risk will continue to grow. Moderate-risk genes create one of the most demanding categories for clinical communication because their effects are meaningful but variable. The new analysis suggests that the next frontier of hereditary cancer care is not simply finding more variants. It is building systems that help patients understand those variants and remain connected to appropriate screening over time. The study’s message is therefore both scientific and operational: identifying risk is only the first step, and the success of precision prevention will ultimately be judged by whether accurate risk information leads to earlier detection and better outcomes.
Subject of Research: Breast cancer screening adherence after multigene panel testing among women with pathogenic variants in moderate-risk genes or empirically increased breast cancer risk.
Article Title: Breast cancer screening adherence after multigene panel testing among women with pathogenic variants in moderate-risk genes or with empirically increased breast cancer risk
Article References: Breast Cancer Research and Treatment, Springer Nature, 2026.
Image Credits: AI Generated
DOI: 10.1007/s10549-026-08020-5
Keywords: breast cancer, genetic testing, multigene panel, pathogenic variants, moderate-risk genes, screening adherence, mammography, breast MRI, hereditary cancer risk, precision medicine
